Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 6.82B 1.02B 916M 844M 766M 1.45B 95.75B 1.49B 10.11B 4.03B 51.3B 3.83B 3.75B 162B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 5.99B 896M 803M 740M 672M 1.27B 83.99B 1.31B 8.86B 3.53B 45B 3.36B 3.29B 142B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
10-27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-14 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-15 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
25-10-28 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-06-04 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
25-05-27 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25-04-25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-17 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
25-03-14 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
25-03-12 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
1 day+1.32%
1 week+5.15%
Current month+5.52%
1 month-17.07%
3 months-10.79%
6 months-7.83%
Current year-0.33%
1 week 2.95
Extreme 2.95
3.1
1 month 2.8
Extreme 2.8
3.73
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 2022-12-25
Corporate Officer/Principal 42 2018-04-17
Corporate Officer/Principal 40 2019-05-22
Director TitleAgeSince
Director/Board Member 40 2025-03-13
Director/Board Member 53 2022-11-10
Director/Board Member 42 2022-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/25 Sell 587,500 0.0283%
7/2/25 Sell

Director

259,600 0.0125%
7/2/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+5.15%-10.53%+18.15% 1.02B
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
-0.81%+0.76%+38.17%+67.08% 388B
-0.48%+2.34%+70.66%+46.02% 365B
-0.93%-0.73%+28.06%+57.50% 307B
-0.10%-0.96%+3.14%+35.53% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average -0.08%+2.34%+34.94%+76.58% 428B
Weighted average by Cap. -0.33%+2.51%+42.73%+96.54%

Financials

2024 2025
Net sales 2.44B 365M 328M 302M 274M 519M 34.25B 533M 3.61B 1.44B 18.35B 1.37B 1.34B 58.01B 2.14B 320M 287M 264M 240M 454M 29.96B 467M 3.16B 1.26B 16.05B 1.2B 1.17B 50.75B
Net income 233M 34.83M 31.24M 28.79M 26.15M 49.48M 3.27B 50.87M 345M 137M 1.75B 131M 128M 5.53B 377M 56.41M 50.59M 46.62M 42.34M 80.13M 5.29B 82.37M 558M 222M 2.83B 212M 207M 8.96B
Net Debt -509M -76.13M -68.27M -62.92M -57.14M -108M -7.14B -111M -753M -300M -3.82B -286M -280M -12.09B -838M -125M -112M -104M -94.14M -178M -11.76B -183M -1.24B -495M -6.3B -471M -461M -19.92B
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
26-11-10 CN¥3.060 +1.32% 117,144,220
26-11-09 CN¥3.020 +1.00% 100,044,616
26-11-06 CN¥2.990 -2.29% 127,714,001
26-11-05 CN¥3.060 +2.34% 176,426,609
26-11-04 CN¥2.990 +2.75% 173,768,594

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock